Regeneron highlights robust pipeline progress, shares trade in a neutral technical range
26.06.2026 - 11:05:12 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 11:04.
Regeneron (US75886F1075) remains one of the larger biotech names on the NASDAQ, with investors tracking a broad portfolio of antibody and gene therapy programs. The focus today is on how the company’s pipeline and existing franchises support the current valuation in the S&P 500 peer group.
What Nasdaq trading data shows
Regeneron Pharmaceuticals shares trade on the NASDAQ under the REGN ticker, with a last close of 620.14 US dollars on 2026-06-25, according to recent price data. MarketBeat price statistics show a market capitalization of around 65 billion US dollars on that basis.
Technical analysis platforms describe the current setup as neutral, with the stock changing hands between a support zone near 594.17 dollars and resistance around 643.47 dollars. One service reports a current price momentum score of 7.33, ranking the name in the upper half of its pharmaceuticals coverage universe. TradingKey technical data cite a mix of buy and sell signals based on moving averages.
Analyst consensus and sector context
Sell-side research houses generally treat Regeneron as a core US large-cap biotech exposure alongside peers such as Amgen and Gilead Sciences. Consensus data compiled by equity research aggregators point to a mixed but broadly positive rating profile, with a majority of analysts on Buy or Outperform and the remainder on Hold. MarketBeat analyst overview shows an average target price above the current share price, reflecting expectations for growth from the pipeline.
In sector terms, Regeneron is positioned in the biotechnology and pharmaceuticals segment, where investors compare valuation multiples and growth rates with the wider NASDAQ-100 healthcare cohort. Recent commentary from US brokers emphasizes the importance of continued sales trends for flagship drugs and a disciplined approach to research and development spending in a higher-rate environment. Bloomberg sector snapshots often highlight the stock’s relatively high absolute price but moderate earnings multiple versus some faster-growing, loss-making biotech names.
Background and price data on Regeneron
All current news, filings and historical prices for the Regeneron shares in one place help investors to track developments around the NASDAQ listing.
The therapies that drive revenue
Regeneron generates the bulk of its revenue from biologic therapies in ophthalmology, immunology and oncology, including the widely used eye treatment Eylea and the asthma and atopic dermatitis drug Dupixent, which it co-develops with Sanofi. The group also markets the cholesterol-lowering antibody Praluent and maintains a growing oncology portfolio, while investing heavily in early-stage gene therapies and next-generation antibody platforms outlined on its corporate site.
Where the shares trade now
The Regeneron shares (US75886F1075) last closed on the NASDAQ at 620.14 US dollars on 2026-06-25, 16:00 Eastern Time, with this level forming the reference point for current market capitalization and technical indicators.
Key data on the Regeneron shares
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- WKN: 881535
- Ticker: REGN
- Trading venue: NASDAQ
- Price (as of 2026-06-25, 16:00): 620.14 USD
- Market cap: 65.11 billion USD (as of 2026-06-25)
- Sector / industry: Biotechnology / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or any other form of financial guidance.
